Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2021 > Vol 2, №4 (2021) > Non-alcoholic fatty liver disease: current aspects of diagnosis in real clinical practice

Non-alcoholic fatty liver disease: current aspects of diagnosis in real clinical practice

Dmitry I. Trukhan

For citation:


  • Abstract
  • About the Author
  • References

Abstract

In the diagnosis and subsequent supervision of patients with non-alcoholic fatty liver disease (NAFLD) and obesity in real clinical practice, the role and importance of the doctor of first contact (therapist and general practitioner) increases. Non-alcoholic fatty liver disease is currently considered as the hepatic component of metabolic syndrome. A diagnostic algorithm for NAFLD at the stage of primary health care is presented. The most difficult question at 2–4 levels of the diagnostic algorithm is the differential diagnosis between NAFLD and alcoholic liver disease. During a pandemic of a novel coronavirus infection (COVID-19), patients with NAFLD or NASH, as a rule, have concomitant metabolic diseases such as diabetes mellitus, arterial hypertension and obesity, and also have to take a large number of potentially hepatotoxic drugs, it is advisable to classify them as elevated risk of infection with SARS-CoV-2, and the severe course of this infection. This allows us to consider NAFLD as dangerous in terms of the severe course of COVID-19, as viral hepatitis, autoimmune hepatitis and liver fibrosis / cirrhosis. It is known that NAFLD is an independent predictor of not only high cardiovascular risks, but also hepatocellular carcinoma and malignant neoplasms of various localization, as well as a number of other comorbid conditions. The review concludes with a clinical observation illustrating the difficulty of early diagnosis of intrahepatic cholangiocarcinoma in a patient with NAFLD and other metabolic risk factors.

Key words: non-alcoholic fatty liver disease, obesity, metabolic syndrome, alcoholic liver disease, diagnostics.

About the Author

Dmitry I. Trukhan 1

1 Omsk State Medical University, Omsk, Russia

References

1. World Health Organization Media Centre. Obesity and overweight. Fact sheet №311. Updated January 2015. www.who.int/mediacentre/factsheets/fs311/en/
2. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study. Lancet 2014; 384 (9945): 766–81. DOI: 10.1016/S0140-6736(14)60460-8
3. Frühbeck G, Toplak H, Woodward E et al. Obesity: The gateway to ill health – an EASO Position Statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 2013; 6 (2): 117–20. DOI: 10.1159/000350627
4. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff (Millwood) 2009; 28 (5): 822–31. DOI: 10.1377/hlthaff.28.5.w822
5. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273 (3): 219–34. DOI: 10.1111/joim.12012
6. World Health Organization Media Centre. Obesity and overweight. Fact sheet no Geneva: World Health Organization; 2013. www.who.int/ news-room/fact-sheets/detail/obesity-and-overweight
7. Defining Obesity. URL: http://asmbs.org/patients/disease-of-obesity
8. Garvey WT, Garber AJ, Mechanick JI et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014; 20 (9): 977–89. DOI: 10.4158/EP14280.PS
9. Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni. Consilium Medicum. 2016; 8: 68–74.
10. Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni, assotsiirovannaia s ozhireniem: vozmozhnosti essentsial'nykh fosfolipidov. Meditsinskii sovet. 2016; 4: 116–22 (in Russian).
11. Rekomendatsii po vedeniiu bol'nykh c metabolicheskim sindromom. Klinicheskie rekomendatsii. Minzdrav Rossii. Moscow, 2013. URL: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-po-kardiologii-2013 (in Russian).
12. Ivashkin V.T., Drapkina O.M., Shul'pekova Iu.O. Diagnostika i lechenie nealkogol'noi zhirovoi bolezni pecheni: metodicheskie rekomendatsii. Мoscow: Izdatel'skii dom "M-Vesti', 2009 (in Russian).
13. Drapkina O.M, Gatsolaeva D.S., Ivashkin V.T. Nealkogol'naia zhirovaia bolezn' pecheni kak komponent metabolicheskogo sindroma. Rossiiskie meditsinskie vesti. 2010; 2: 72–8 (in Russian).
14. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239: 192–202. DOI: 10.1016/j.atherosclerosis.2015.01.001
15. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obesepatients undergoing bariatric surgery. J Hepatol 206; 45 (4): 600–6. DOI: 10.1016/j.jhep.2006.06.013
16. Gaggini M, Morelli M, Buzzigoli E et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5 (5): 1544–60. DOI: 10.3390/nu5051544
17. Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers,in non-alcoholic fatty liver disease. J Diabetes Investig 2013; 4 (6): 517–24. DOI: 10.1111/jdi.12107
18. Williamson RM, Price JF, Glancy S et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care 2011; 34 (5): 1139–44. DOI: 10.2337/dc10-2229
19. Trukhan D.I., Filimonov S.N. Klinika, diagnostika i lechenie osnovnykh endokrinnykh i gematologicheskikh zabolevanii. Novokuznetsk: Poligrafist, 2015 (in Russian).
20. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013; 167 (4): 1109–17. DOI: 10.1016/j.ijcard.2012.09.085
21. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51 (11): 1947–53. DOI: 10.1007/s00125-008-1135-4
22. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59 (3): 1174–97. DOI: 10.1002/hep.26717
23. Trukhan D.I., Viktorova I.A., Safonov A.D. Bolezni pecheni. Saint Petersburg: SpetsLit, 2019 (in Russian).
24. Trukhan D.I., Bilevich O.A. Nealkogol'naia zhirovaia bolezn' pecheni, assotsiirovannaia s ozhireniem: vozmozhnosti ursodezoksikholevoi kisloty. Meditsinskii sovet. 2019; 6: 86–94 (in Russian).
25. Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Nealkogol'naia zhirovaia bolezn' pecheni u vzroslykh: klinika, diagnostika, lechenie. Rekomendatsii dlia terapevtov, tret'ia versiia. Eksperimental'naia i klinicheskaia gastroenterologiia. 2021; 185 (1): 4–52. DOI: 10.31146/1682-8658-ecg-185-1-4-52 (in Russian).
26. Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Sindrom povyshennoi epitelial'noi pronitsaemosti v klinicheskoi praktike. Mul'tidistsiplinarnyi natsional'nyi konsensus. Kardiovaskuliarnaia terapiia i profilaktika. 2021; 20 (1): 121–278. DOI: 10.15829/1728-8800-2021-2758 (in Russian).
27. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: 5–10. DOI: 10.1097/01.mcg. 0000168638.84840.ff
28. Younossi ZM, Stepanova M, Affendy M et al. Izmenenie rasprostranennosti osnovnykh khronicheskikh boleznei pecheni v SShA s 1998 po 2008 g. Klinicheskaia gastroenterologiia i gepatologiia. Russkoe izdanie. 2011; 5: 261–7 (in Russian).
29. Jarvis H, Craig D, Barker R et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med 2020; 17 (4): e1003100. DOI: 10.1371/journal.pmed.1003100
30. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37 (5): 1202–19. DOI: 10.1053/jhep.2003.50193
31. Drapkina O, Ivashkin V. Prevalence and risk factors for non–alcogolic fatty liver disease in Russian federation. International Liver Congress 2010. Abstract book. Р. 138.
32. Podvedenie itogov vserossiiskogo issledovaniia DIREG-2. URL: http://ria-ami.ru/read/19366 (in Russian).
33. Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni v praktike vracha pervogo kontakta. Klinicheskie perspektivy gastroenterologii, gepatologii. 2012; 1: 3–9 (in Russian).
34. Trukhan D.I., Tarasova L.V., Viktorova I.A. Rol' vracha obshchei praktiki v diagnostike i lechenii nealkogol'noi zhirovoi bolezni pecheni. Spravochnik vracha obshchei praktiki. 2013; 3: 58–68 (in Russian).
35. Trukhan D.I. Vozmozhnosti gepatoprotektora s prebioticheskim deistviem. Meditsinskii sovet. 2016; 9: 64–9 (in Russian).
36. Butov M.A., Ardatova V.B., Shelukhina S.V. Disfunktsii biliarnogo trakta: diagnostika, medikamentoznaia korrektsiia. Riazan', 2004 (in Russian).
37. Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni v praktike vracha pervogo kontakta. Poliklinika. 2013; 1: 63–8. (in Russian).
38. Trukhan D.I., Filimonov S.N. Differentsial'nyi diagnoz osnovnykh gastroenterologicheskikh sindromov i simptomov. Мoscow: Prakticheskaia meditsina, 2016 (in Russian).
39. Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni: lechebnye i dieticheskie rekomendatsii vracha pervogo kontakta. Consilium Medicum. Gastroenterologiia. 2014; 2: 10–5 (in Russian).
40. Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni: lechebnye i dieticheskie rekomendatsii na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Meditsinskii sovet. 2015; 17: 78–84 (in Russian).
41. Trukhan D.I. Sindrom pechenochnoi entsefalopatii. Aktual'nye aspekty diagnostiki i lecheniia. Meditsinskii sovet. 2016; 14: 80–7 (in Russian).
42. Trukhan D.I., Viktorova I.A., Safonov A.D. Bolezni pecheni. Saint Petersburg: Foliant, 2010 (in Russian).
43. Banerjee R, Pavlides M, Tunnicliffe EM et al. Multiparametricmagnetic resonance for the non-invasive diagnosis of liver dis-ease. J Hepatol 2014; 60 (1): 69–77. DOI: 10.1016/j.jhep.2013.09.002
44. Sing S, Venkateshh SК, Wang Z et al. Performance of magneticresonance elastographyin staging liver fi brosis. A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13 (3): 440–51.e6. DOI: 10.1016/j.cgh.2014.09.046
45. Diomidova V.N., Tarasova L.V., Trukhan D.I. et al. Informativnost' elastografii sdvigovoi volnoi s elastometriei pri nealkogol'noi zhirovoi bolezni pecheni. Prakticheskaia meditsina. 2018; 1 (112): 81–5 (in Russian).
46. Diomidova V.N., Tarasova L.V., Trukhan D.I, Tsyganova Iu.V. Sravnitel'naia otsenka elastometricheskikh pokazatelei zhestkosti pecheni pri alkogol'noi i nealkogol'noi ee bolezni. Eksperimental'naia i klinicheskaia gastroenterologiia. 2018; 7: 52–6 (in Russian).
47. Tarasova L.V., Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni: dieticheskie i lechebnye rekomendatsii vracha obshchei praktiki. Terapevt. 2013; 8: 4–15 (in Russian).
48. Trukhan D.I., Mazurov A.L. Lekarstvennye porazheniia pecheni: aktual'nye voprosy diagnostiki i lecheniia. Meditsinskii sovet. 2016; 5: 70–3 (in Russian).
49. Ratziu V. A proposal for current and future therapeutic strategies for NASH. EASL Special Conference «NAFLD/NASH and Related Metabolic Disease». Bologna, Italy, 2009. Program and Abstracts. P. 29.
50. Maev IV, Samsonov AA, Lazebnik LB et al. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther 2020; 37 (11): 4627–40. DOI: 10.1007/s12325-020-01493-w
51. Mahli A, Hellerbrand C. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease. Dig Dis 2016; 34 (Suppl. 1): 32–9. DOI: 10.1159/000447279
52. Lazebnik L.B., Golovanova E.V., Tarasova L.V. et al. Alkogol'naia bolezn' pecheni (ABP) u vzroslykh. Eksperimental'naia i klinicheskaia gastroenterologiia. 2020; 2 (174): 4–28 (in Russian).
53. Lazebnik L.B., Golovanova E.V., Eremina E.Iu. et al. Klinicheskie rekomendatsii: Alkogol'naia bolezn' pecheni u vzroslykh. Terapiia. 2020; 4: 10–35 (in Russian).
54. Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. Nutr Rev 2011; 69 (8): 419–31. DOI: 10.1111/j.1753-4887.2011.00403.x
55. Traversy G, Chaput JP. Alcohol Consumption and Obesity: An Update. Curr Obes Rep 2015; 4 (1): 122–30. DOI: 10.1007/s13679-014-0129-4
56. Bueverov A.O., Bogomolov P.O. Nealkogol'naia zhirovaia bolezn' pecheni: obosnovanie patogeneticheskoi terapii. Klinicheskie perspektivy gastroenterologii, gepatologii. 2009; 1: 3–8 (in Russian).
57. Tarasova L.V., Trukhan D.I. Nealkogol'naia zhirovaia bolezn' pecheni: dieticheskie i lechebnye rekomendatsii vracha obshchei praktiki. Terapevt. 2013; 8: 4–15 (in Russian).
58. Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Osobennosti vedeniia komorbidnykh patsientov v period pandemii novoi koronavirusnoi infektsii (COVID-19). Natsional'nyi Konsensus 2020. Kardiovaskuliarnaia terapiia i profilaktika. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).
59. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 2020; 30 (8): 1236–48. DOI: 10.1016/j.numecd.2020.05.014
60. Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr 2020; 14 (5): 825–7. DOI: 10.1016/j.dsx.2020.06.013
61. Gao F, Zheng KI, Wang XB et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol 2021; 36 (1): 204–7. DOI: 10.1111/jgh.15112
62. Grinevich V.B., Kravchuk Iu.A., Ped' V.I. et al. Vedenie patsientov s zabolevaniiami organov pishchevareniia v period pandemii COVID-19. Klinicheskie rekomendatsii Rossiiskogo nauchnogo meditsinskogo obshchestva terapevtov i Nauchnogo obshchestva gastroenterologov Rossii (2-e izdanie). Eksperimental'naia i klinicheskaia gastroenterologiia. 2021; 3: 5–82. DOI: 10.31146/1682-8658-ecg-187-3-5-82 (in Russian).
63. Singh MK, Mobeen A, Chandra A et al. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med 2021. 130: 104219. DOI: 10.1016/j.compbiomed.2021.104219
64. Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab Syndr 2021; 15 (3): 813–22. DOI: 10.1016/j.dsx.2021.03.019
65. Hegyi PJ, Váncsa S, Ocskay K et al. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis. Front Med (Lausanne) 2021; 8: 626425. DOI: 10.3389/fmed.2021.626425
66. Tikhonov S.V., Dekkanova V.D., Vinnichuk S.A. et al. Ozhirenie, nealkogol'naia zhirovaia bolezn' pecheni, COVID-19. Opasnye sviazi. Meditsinskii sovet. 2021; 5: 76–83. DOI: 10.21518/2079-701X-2021-5-76-83 (in Russian).
67. Grishechkina I.A., Viktorova I.A., Trukhan D.I., Kondrat'eva N.A. Aktual'nye aspekty diagnostiki vnutripechenochnoi kholangiokartsinomy. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii. 2016; 11–1: 61–5 (in Russian).
68. Rizdi S, Gores GJ. Pathogenesis, Diagnosis and Management of Cholangiocarcinoma. Gastroenterology 2013;  145 (6). DOI: 10.1053/3gastro2013.10.013
69. Brown KM, Parmar AD, Geller DA. Intrahepatic Cholangiocarcinomа. Surg Oncol Clin N Am 2014; 2: 231–46. DOI: 10.1016/j.soc.2013.10.004
70. Dvoretskii L.I. Paraneoplasticheskie sindromy. Spravochnik poliklinicheskogo vracha, 2003, 3: 23–8 (in Russian).

For citation:Trukhan D.I. Non-alcoholic fatty liver disease: current aspects of diagnosis in real clinical practice. Clinical review for general practice. 2021; 4: 40–50. DOI: 10.47407/kr2021.2.4.00059


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru